

PA Criteria	Criteria Details						
<b>Covered Uses (FDA approved indication)</b>	Susvimo ocular implant, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.						
<b>Exclusion Criteria</b>	None.						
<b>Required Medical Information</b>	Baseline Best-Corrected Visual Acuity (BCVA) score must be provided Medical records supporting the request must be provided.						
<b>Age Restriction</b>	None.						
<b>Prescriber Restrictions</b>	Must be prescribed by or in consultation with an ophthalmologist.						
<b>Coverage Duration</b>	Up to 2 years. Dose will be approved according to the FDA approved labeling or within accepted standards of medical practice.						
<b>Other Criteria/Information</b>	Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="500 926 1511 1073"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J2779</td> <td>Susvimo (ranibizumab)</td> <td><b>Billing unit: 0.1 mg</b>  10 mg/0.1mL SDV</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	J2779	Susvimo (ranibizumab)	<b>Billing unit: 0.1 mg</b>  10 mg/0.1mL SDV
HCPCS	Description	Billing Units/How Supplied					
J2779	Susvimo (ranibizumab)	<b>Billing unit: 0.1 mg</b>  10 mg/0.1mL SDV					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	8/21/2025	Pharmacy & Therapeutics (P&T) Committee	8/21/2025